Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients

NCT: NCT05704751 · WITHDRAWN

NCT IDNCT05704751
StatusWITHDRAWN
Start Date2023-10-27
Completion2025-08-12
SponsorBarts & The London NHS Trust (OTHER)
First posted
Last updated

Brief Summary

This study is designed to evaluate the feasibility of using intra-operative ECAP and Late-Response (LR) recordings for confirmation of activating the neuronal target of the dorsal column in a single-stage SCS lead placement procedure. The collected ECAP and LR data will be analysed post-hoc to further evaluate its utility for determining the laterality of lead placement with respect to the physiologic midline of the dorsal column.

Frequently Asked Questions

What is EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients?

EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients is a clinical trial registered under NCT05704751. Current status: WITHDRAWN.

What is the status of NCT05704751?

The current status of NCT05704751 (EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients) is: WITHDRAWN.

When did EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients start?

EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients started on 2023-10-27.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑